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Background. Malnutrition in human immunodeficiency virus (HIV)–infected individuals is associated with
faster disease progression, higher mortality rates, and suboptimal response to antiretroviral therapy (ART).
Methods. We conducted a prospective interventional study to evaluate the effects of an oral macronutrient
supplement among HIV-infected adults in South India. Patients attending Tuberculosis Research Centre clinics
from June 2005 through December 2007 had baseline nutritional assessment and laboratory investigations per-
formed. Patients at 1 center received nutritional counseling and standard care, whereas patients at 2 centers
additionally received a macronutrient providing 400 cal and 15 g of protein daily. Study outcomes were changes
in anthropometry, body composition, blood chemistry, and immune status at 6 months.
Results. In total, 636 ART-naive patients were enrolled in the study; 361 completed 6 months of follow-up
(282 received supplements and 79 received standard care). Mean age  standard deviation (SD) was years,31 7
mean weight  SD was kg, and 42% were male. Significant increases in body weight, body mass index,50 10
midarm circumference, fat-free mass, and body cell mass were observed in the supplement group but not in the
control group at 6 months; gains were greater in patients with CD4 cell counts !200 cells/mL. No changes were
observed in lipid levels, whereas the CD4 cell count decreased in the control group. However, after adjusting for
baseline differences, these changes were not statistically significantly different between the groups.
Conclusions. Macronutrient supplementation did not result in significantly increased weight gain compared
with standard care (including nutritional counseling) among patients with moderately advanced HIV disease. The
effect of supplementation on specific subsets of patients and on preserving immune function needs further research.
During the past decade, which saw wide and easy
access to antiretroviral therapy (ART) in the devel-
oped world, a significant number of life-years were
saved among patients infected with human immu-
nodeficiency virus (HIV) [1]. Recent guidelines rec-
ommend initiation of ART before CD4 cell counts
decrease below 350 cells/mL [2]. However, in resource-
poor countries of Africa and Asia, where most of the
world’s HIV-infected people live and where food in-
security is widespread [3, 4], diagnosis of HIV infec-
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tion is often made only at the advanced stage. Fur-
thermore, malnutrition is endemic in these countries
and is a common manifestation among HIV-infected
individuals. We have previously shown that HIV-in-
fected individuals have higher rates of malnutrition,
anemia, and hypoalbuminemia than do socioecon-
omically matched HIV-uninfected individuals, despite
similar caloric intake [5, 6].
Rates of HIV disease progression and mortality are
higher in the presence of severe malnutrition [7, 8].
Furthermore, malnourished patients have a higher risk
of death and suboptimal response to treatment when
ART is initiated [9]. Studies of body composition have
identified predominant loss of either lean muscle mass
or fat mass during AIDS wasting [10]. Although ran-
domized trials of nutritional supplementation are few,
it has been shown that it is acceptable and feasible to
improve food intake in malnourished HIV-infected pa-
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tients [11–13]. The National AIDS Control Program in India
began its free antiretroviral treatment program in 2004 and
targeted patients with advanced (stage 3 or 4) disease or CD4
cell counts !200 cells/mL. Those not eligible for ART receive
multivitamins and cotrimoxazole prophylaxis, as well as treat-
ment for associated opportunistic infections. We hypothesized
that supplementation with additional calories and protein
would improve nutritional status and possibly have an effect
on the body composition and immunologic status of these
individuals. At the Tuberculosis Research Centre (TRC), Tamil
Nadu, South India, we conducted a prospective interventional
study to evaluate the effects of an energy-dense macronutrient
supplement provided for 6 months on the anthropometric,
body composition, and immunologic status of HIV-infected
adults at different stages of disease. The study was conducted
in collaboration and with financial support from the World
Food Program in India.
METHODS
Study population. HIV-infected individuals attending local
government hospitals for medical care were referred to TRC
clinics at Chennai and Madurai, India, for screening and en-
rollment into various ongoing research studies. They were ap-
proached for participation in this prospective interventional
study. To be eligible, they had to be 18 years or older, ART
naive, and willing to consume the supplement as instructed
and to follow study procedures. Patients were excluded if they
had any of the following: active tuberculosis or other serious
opportunistic infections, dysphagia, odynophagia, severe di-
arrhea (16 watery stools per day for 7 days), allergy to soy-
bean, or unwillingness to follow study protocols. Informed con-
sent was obtained from all patients, and the study was approved
by the Institutional Ethics Committee of the TRC.
Nutritional assessment. At the first visit, a history was
taken, a physical examination was performed, and a blood sam-
ple was obtained for analysis (blood cell counts, chemical anal-
ysis, and CD4 cell count). The study nutritionist obtained a
24-h recall diet history [14]; Digest [15], a software package
specially designed to analyze South Indian diets, was used to
calculate the intake of calories, protein, and fat.
At the second visit and all subsequent visits, nutritional status
was assessed. Height (to the nearest centimeter), weight (to the
nearest 0.1 kg), and midarm circumference (to the nearest 0.1
cm) were measured. Anthropometric measurements were per-
formed by 2 trained nutritionists (one nutritionist each in
Chennai and Madurai), and interobserver variability between
them was limited by standardization of methods before study
initiation. Bioelectrical impedance measurements were ob-
tained with a bioimpedance analyzer (Quantum handheld an-
alyzer; RJL Systems) using standard techniques at the Chennai
center only [16].
Of the 3 outpatient clinics (2 in Chennai and 1 in Madurai),
patients attending one of the clinics in Chennai received stan-
dard of care alone and served as the control group, whereas
those attending the other clinic in Chennai and the clinic in
Madurai received the nutritional supplement along with stan-
dard of care. Standard of care consisted of prophylaxis and
treatment of common opportunistic infections (including co-
trimoxazole for all and isoniazid in some cases), multivitamin
tablets (vitamin A, 5000 IU; vitamin D, 200 IU; vitamin E, 7.5
mg; vitamin B, 2.5 mg; vitamin C, 40 mg; nicotinamide, 25
mg; d-pantothenol, 2.5 mg; folic acid, 500 mg; vitamin B12, 2.5
mg; copper sulfate pentahydrate, 0.1 mg; magnesium sulfate
monohydrate, 0.01 mg; zinc sulfate, 31.2 mg; and potassium
iodide, 15 mg), nutritional counseling, and psychosocial sup-
port. Compliance with drug therapy was checked by pill counts
during monthly visits.
During the intervention period, patients were assessed clin-
ically every month, whereas 24-h dietary recall, anthropometric
parameters, body composition, blood chemical analysis, and
CD4 cell counts were measured at the 6-month visit. Because
of ethical concerns about withholding nutritional supplements
from HIV-infected patients, the selection of groups (control vs
supplement) was done at a ratio of 1:3. After 6 months of the
study period, all patients (including those in the control group)
were offered the supplement.
Nutritional supplement. The high-calorie, high-protein
macronutrient supplement Indiamix, which was provided by
the World Food Program in India, is a blended, fortified mix-
ture of whole wheat and soya bean flour fortified with vitamins
A, B1, B2, B12, and C as well as niacin and folic acid but no
iron. One hundred grams of the supplement provided 400 cal,
15 g of protein, 6 g of fat, and 1 recommended daily allowance
of each vitamin. Study participants were instructed to consume
100 g/d and were given a month’s supply of Indiamix, which
was available in 3-kg packs. Study nutritionists discussed var-
ious recipes and suggested ways of preparing the supplement—
the easiest was to cook it as porridge with water. Compliance
with the supplement regimen was checked by random home
visits by fieldworkers and by questioning patients during their
monthly visits. Additional food packets were issued to the par-
ticipants if required to avoid sharing of the rations with other
family members.
Outcomes. The outcomes assessed were changes in an-
thropometric parameters (weight; body mass index [BMI], cal-
culated as the weight in kilograms divided by the square of
height in meters; and midarm circumference), blood chemical
analysis (hemoglobin, serum albumin, triglyceride, and cho-
lesterol levels), immune status (CD4 cell count), and body com-
position (fat, fat-free mass, and body cell mass).
Data analysis. The distribution of all variables was
checked, and skewed variables were log transformed. The mean,
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Table 1. Comparison of Baseline Characteristics of Patients Who Completed 6 Months of
Follow-up (Completers) versus Those Who Did Not (Noncompleters)
Characteristic
Completers Noncompleters
P
No. of
patients Value
No. of
patients Value
Age, years 361 31  7 275 32  7 .03
Weight, kg 361 50.3  10.4 275 50.0  9.5 .71
BMI 361 20.6  3.9 275 19.9  3.4 .02
Midarm circumference, cm 361 23.7  3.5 275 23.5  3.8 .35
Hemoglobin level, g/dL 357 11.9  1.8 260 11.9  2.1 .87
Albumin level, g/dL 312 4.0  0.6 210 3.8  0.6 !.001
Total cholesterol level, mg/dL 308 144  34.7 209 137  29.9 .01
Triglyceride level, mg/dL 305 124  66.7 208 122  61 .77
CD4 cell count, cells/mL
Mean  SD 357 391  245 259 298  200 !.001
Median (range) 357 338 (24–1550) 259 279 (6–1247) …
Caloric intake, kcal/day 361 1846  533 274 1853  609 .87
Protein intake, g/day 361 57  23 274 60  30 .10
Fat intake, g/day 361 35  18 274 36  21 .52
Body fat, kg 149 12.3  8.6 146 10.6  6.9 .07
Fat-free mass, kg 149 40.5  8.3 146 41.2  8.5 .44
Body cell mass, kg 149 18.5  4.3 146 18.8  4.4 .59
NOTE. Data are means  standard deviations (SDs), unless otherwise indicated. BMI, body mass index.
the median, and the 25th and 75th percentiles were determined
for all continuous variables. Because there were a sizeable num-
ber of exclusions from the study, we compared the baseline
characteristics of those who completed the study with those
who did not, using the independent t test and the x2 test.
Mixed-model analysis incorporating the repeated measure-
ments was used to analyze the absolute changes at 6 months
in anthropometric parameters, laboratory measurements, and
body composition between the supplement and control groups
after controlling for baseline CD4 cell count, age, and sex.
Analysis was also performed by stage of immunosuppression,
with patients in the following CD4 cell count categories being
compared: !200 cells/mL, 200–499 cells/mL, and 500 cells/mL.
Data were analyzed using SAS statistical software, version 9.1.0
(SAS Institute).
RESULTS
From June 2005 through December 2007, a total of 636 HIV-
infected individuals were screened and enrolled in the study.
Two hundred seventy-five did not initiate use of the supple-
ment, became ineligible, or discontinued use of the supplement
within the first few weeks because of a variety of reasons (non-
completers). Of these, ∼40% initiated ART and another 20%
were hospitalized for management of their medical problems
and therefore were ineligible for inclusion. A total of 10% of
patients died, and 30% discontinued participation in the study
for various reasons, such as distaste for food, nausea, early
satiety, inability to cook, and/or embarrassment regarding car-
rying the supplement home. A total of 361 patients completed
6 months of supplementation (completers) and were available
for evaluation. The baseline characteristics of the noncomple-
ters and completers are given in Table 1. The noncompleters
were older and had lower BMIs, CD4 cell counts, serum al-
bumin levels, and blood cholesterol levels, indicating more ad-
vanced disease. However, the 2 groups were similar in terms
of marital status, income level, years of education (two-thirds
had !8 years of schooling), dietary intake, and body weight
and composition. No imputation was done for missing data,
and only data from completers were used for analysis.
Of the 361 completers, 282 were in the supplement group
and 79 were in the control group. The mean age  SD was
30.9  7 years, and the mean weight  SD was 50.3  10.4
kg. A total of 36% of men and 30% of women were severely
malnourished, with a BMI !18.5 at baseline. The patients at-
tending the 3 centers were demographically similar in terms of
socioeconomic status, literacy levels, and dietary habits. Most
patients belonged to the lower socioeconomic strata, with a
monthly income of 2000–5000 rupees (!$100). Most patients
were asymptomatic at the time of enrollment, although a third
had a history of tuberculosis treatment. At baseline, body
weight, BMI, serum albumin level, and body composition were
comparable between the supplement and control groups (Table
2). However, CD4 cell counts were significantly higher in the
control group, but caloric and protein intake were lower.
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Table 2. Comparison of Baseline Characteristics of Patients Who Received Supplements (Supplement
Group) versus Those Who Did Not (Control Group)
Characteristic
Supplement group Control group
PNo. of patients Value No. of patients Value
Weight, kg 282 49.9  9.8 79 51.6  12.1 .24
BMI 282 20.5  3.7 79 21.1  4.7 .28
Midarm circumference, cm 282 23.7  3.3 79 24.1  4.2 .39
Hemoglobin level, g/dL 282 11.8  1.8 75 12.1  1.9 .18
Albumin level, g/dL 260 4.0  0.6 52 3.9  0.4 .22
Total cholesterol level, mg/dL 256 143.5  35.6 52 148.2  29.4 .37
Triglyceride level, log mg/dL 254 4.7  0.4 51 4.7  0.5 .95
CD4 cell count, log cells/mL 282 5.7  0.7 75 6.0  0.6 !.001
CD4 cell count, absolute
cells/mL 282 365  233 75 488  266 .001
Caloric intake, kcal/day 282 1911  543 75 1616  427 !.001
Protein intake, g/day 282 58.2  23.3 75 51.0  20.1 .01
Body fat, kg 113 11.7  8.1 36 14.0  9.9 .16
Fat-free mass, kg 113 40.7  8.5 36 39.9  8.0 .63
Body cell mass, kg 113 18.6  4.3 36 18.3  4.1 .69
NOTE. Data are means  standard deviations. BMI, body mass index.
Table 3. Changes in Various Parameters at 6 Months in the Supplement and Control Groups, with Comparison of Differences
Parameter
Absolute change at 6 months from baseline within groups
Difference of differences
at 6 months
Supplement group Control group
Baseline estimate
Change at 6 months
(change 1) Baseline estimate
Change at 6 months
(change 2)
Weight, kg 51.3 (50.1 to 52.5) 0.9 (1.2 to 0.6)a 52.3 (50.1 to 54.6) 0.6 (0.02 to 1.3) 0.3 (1.0 to 0.4)
BMI 20.5 (20.1 to 21.0) 0.4 (0.5 to 0.2)a 20.9 (19.9 to 21.7) 0.2 (0.1 to 0.5) 0.2 (0.5 to 0.1)
Midarm circumference, cm 24.1 (23.7 to 24.5) 0.6 (0.9 to 0.3)a 24.2 (23.4 to 25.0) 0.4 (0.1 to 0.9)  0.2 (0.7 to 0.4)
Hemoglobin level, g/dL 12.1 (11.9 to 12.2) 0.02 (0.2 to 0.2) 12.2 (11.9 to 12.6) 0.1 (0.3 to 0.5) 0.1 (0.3 to 0.5)
Albumin level, g/dL 3.9 (3.9 to 4.0) 0.13 (0.06 to 0.2)a 3.8 (3.7 to 3.9) 0.15 (0.3 to 0.01) 0.01 (0.2 to 0.2)
Total cholesterol level, mg/dL 144 (139.9 to 147.3) 0.4 (4.6 to 5.4) 143 (136 to 151) 4.5 (6.3 to 15.3) 4.1 (7.8 to 16)
Triglyceride level, log mg/dL 4.7 (4.6 to 4.8) 0.02 (0.1 to 0.04) 4.6 (4.5 to 4.8) 0.1 (0.3 to 0.02) 0.1 (0.3 to 0.05)
CD4 cell count, log cells/mL 5.6 (5.6 to 5.7) 0.01 (0.07 to 0.06) 5.9 (5.8 to 6.1) 0.14 (0.01 to 0.3)a 0.13 (0.3 to 0.02)
CD4 cell count, absolute
cells/mL 358 (331 to 385) 12.5 (36 to 10.6) 443 (392 to 494) 59.8 (11.6 to 107.9) 72.3 (18.9 to 125.7)
Body fat by BIA, kg 11.9 (10.5 to 13.2) 0.5 (0.1 to 1.0) 12.4 (9.8 to 14.9) 0.4 (0.8 to 1.5) 0.09 (1.4 to 1.2)
Fat-free mass by BIA, kg 41.7 (40.8 to 42.6) 1.0 (1.4 to 0.7)a 41.5 (39.7 to 43.2) 0.5 (0.3 to 1.2) 0.6 (1.4 to 0.3)
Body cell mass by BIA, kg 19.1 (18.6 to 19.6) 0.5 (0.8 to 0.2)a 19.1 (18.2 to 20.1) 0.2 (0.4 to 0.9) 0.28 (1.0 to 0.4)
NOTE. Data in parentheses are 95% confidence intervals. Estimates were calculated by repeated-measurements analysis of variance, adjusting for baseline
CD4 cell count, age, and sex. The difference of the differences between the 2 groups (change 1 and change 2) was not statistically significant for any of the
parameters. BIA, bioimpedance analysis; BMI, body mass index.
a Significant change from baseline at 6 months ( ).P ! .001
At the end of 6 months, the supplement group showed sig-
nificant increases in weight, BMI, and midarm circumference,
whereas in the control group the only significant change was
a decrease in log CD4 cell count (Table 3). However, using
mixed-model analysis and adjusting for the baseline differences
in CD4 cell count, age, and sex between the 2 groups, none of
these changes were statistically significant.
Patients who received the supplement were further catego-
rized into 3 categories based on level of immunodeficiency:
CD4 cell count !200 cells/mL, CD4 cell count of 200–499 cells/
mL, and CD4 count 500 cells/mL. Table 4 shows the changes
at 6 months from baseline in these 3 groups of patients. A
significant increase was noticed in weight, BMI, and midarm
circumference in all 3 immune categories, whereas an increase
in fat-free mass and body cell mass was observed in patients
in the mild to moderately immunodeficient categories. The
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Table 4. Changes in Various Parameters at 6 Months in the Supplement Group, Categorized by Level of Immunodeficiency
Parameter
Absolute change at 6 months from baseline, by CD4 cell count
!200 cells/mL (n p 81) 200–499 cells/mL (n p 133) 500 cells/mL (n p 68)
Baseline estimate Change at 6 months Baseline estimate Change at 6 months Baseline estimate Change at 6 months
Weight, kg 48.6 (46.5 to 50.7) 1.2 (1.8 to 0.6)a 52.2 (50.5 to 53.8) 0.8 (1.3 to 0.4)a 52.1 (49.7 to 54.4) 0.7 (1.4 to 0.07)a
BMI 19.4 (18.7 to 20.3) 0.4 (0.7 to 0.1)a 20.9 (20.3 to 21.5) 0.3 (0.5 to 0.1)a 21.0 (20.1 to 21.9) 0.3 (0.6 to 0.04)a
Midarm circumference, cm 23.1 (22.4 to 23.9) 0.8 (1.3 to 0.3)a 24.5 (23.9 to 25.1) 0.5 (0.9 to 0.1)a 24.4 (23.5 to 25.2) 0.5 (1.1 to 0.02)a
Hemoglobin level, g/dL 11.0 (10.7 to 11.3) 0.3 (0.7 to 0.03) 12.3 (12.1 to 12.6) 0.08 (0.2 to 0.3) 12.6 (12.2 to 12.9) 0.1 (0.2 to 0.5)
Albumin level, g/dL 3.7 (3.6 to 3.8) 0.06 (0.2 to 0.07) 4.0 (3.9 to 4.2) 0.2 (0.1 to 0.3)a 4.1 (3.9 to 4.2) 0.08 (0.2 to 0.07)
Cholesterol level, mg/dL 128 (122 to 135) 2.5 (7.6 to 12.6) 145 (140 to 150) 2.0 (9.4 to 5.5) 154 (147 to 161) 2.6 (7.7 to 12.9)
Triglyceride level, log mg/dL 4.7 (4.6 to 4.8) 0.04 (0.08 to 0.2) 4.7 (4.6 to 4.7) 0.02 (0.1 to 0.1) 4.7 (4.6 to 4.8) 0.08 (0.2 to 0.04)
CD4 cell count, log cells/mL 4.8 (4.7 to 4.9) 0.09 (0.03 to 0.2) 5.8 (5.7 to 5.8) 0.01 (0.1 to 0.08) 6.4 (6.3 to 6.5) 0.1 (0.2 to 0.02)
CD4 cell count, absolute
cells/mL 131 (108 to 154) 36.6 (80 to 6.3) 336 (318 to 354) 23.7 (56.8 to 9.4) 690 (664 to 716) 34.9 (11.9 to 81.7)
Body fat by BIA, kg 10.8 (8.5 to 13.1) 0.6 (0.5 to 1.6) 11.5 (9.7 to 13.2) 0.4 (0.4 to 1.2) 13.2 (10.4 to 15.9) 0.4 (0.9 to 1.6)
Fat-free mass by BIA, kg 41.5 (39.7 to 43.2) 1.2 (1.8 to 0.6)a 41.8 (40.5 to 43.1) 1.2 (1.6 to 0.7)a 41.2 (39.2 to 43.3) 0.4 (0.3 to 1.2)
Body cell mass by BIA, kg 19.1 (18.1 to 20) 0.7 (1.4 to 0.1)a 19.2 (18.5 to 19.9) 0.6 (1.0 to 0.1)a 18.8 (17.7 to 19.9) 0.03 (0.7 to 0.8)
NOTE. Data in parentheses are 95% confidence intervals. Estimates were calculated by repeated-measurements analysis of variance, adjusting for baseline
CD4 cell count, age, and sex. BIA, bioimpedance analysis; BMI, body mass index.
a Significant increase or decrease from baseline at 6 months ( ).P ! .05
absolute changes, however, were not significantly different be-
tween the 3 categories of patients, except for log CD4 cell count
between the !200 cells/mL and 500 cells/mL CD4 cell count
groups.
DISCUSSION
In this nonrandomized comparison of macronutrient supple-
mentation among HIV-infected patients at various stages of
HIV disease in India, we observed an improvement in various
nutritional parameters in the supplement group, but this was
not statistically significantly different from the members of the
control group, who were provided standard of care. There could
be several potential reasons for the lack of noticeable effect,
some of which are related to study design and others to bio-
logical and behavioral factors. Patients who were severely ill,
who were about to initiate ART, or who required hospitalization
were not included in the study, and this may have been the
group most likely to benefit. Randomized clinical trials, while
the ideal way to prove the efficacy of an intervention, present
ethical problems when dealing with nutritional supplements.
Often, all patients are uniformly food insecure, and investi-
gators find it awkward and uncomfortable to allocate extra food
to some and not to other patients in their care. We tried to
overcome this difficulty by performing a nonrandomized com-
parison enrolling patients at different sites into the 2 arms and
providing access to the supplement to all individuals at the end
of the study period. This resulted in enrollment of patients with
different baseline characteristics; the problem was addressed
by performing mixed-model analysis controlling for baseline
differences.
Furthermore, we did not analyze the record of hospitaliza-
tions or intercurrent infections or compare deaths between the
2 groups; hence, the effect of supplementation on mortality
and morbidity was not determined. Although caloric and pro-
tein intakes were statistically different between the supplement
and control groups, we believe that this finding was likely due
to chance. We also had a sizeable number of patients who were
excluded in the first days and weeks of the study from the
supplement group (mainly because of initiation of ART or
disinterest in the intervention), leading to a further bias in our
comparison groups. Finally, both groups were provided excel-
lent medical care, treatment for and prevention of opportunistic
infections, multivitamins, and nutritional counseling, which
could have led to changes in patient behavior (and diet) that
reduced the difference between the 2 groups at 6 months.
A recent review of randomized clinical trials of macronu-
trient supplements in HIV-infected populations did not observe
an effect on body weight, BMI, or clinical outcomes [17]. It is
noteworthy, however, that one multicentric study of whey pro-
tein supplement in weight-stable patients with a history of
weight loss found an increase in CD4 cell counts relative to
those in control subjects, even though there was no significant
improvement in weight [12]. Only 2 trials have been conducted
in resource-poor settings. Cantrell et al [18] found improved
adherence to ART among food-insecure patients provided mac-
ronutrients, compared with that among patients who were not.
A randomized trial in Malawi found that the ready-to-use
spread was significantly more effective than corn soy blend in
increasing BMI among HIV-infected adults with wasting; no
differences in CD4 cell counts, viral loads, or mortality were
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observed between the 2 groups. However, there was no group
that did not receive supplementation [19]. This suggests that
end points for future supplementation trials should be carefully
chosen (a slowing of decline in immune function is an obser-
vation made by us and Sattler et al [12] and may be worth
exploring further).
As HIV infection progresses, it produces a catabolic state and
increased susceptibility to other infections; when this is com-
pounded by a lack of food, progressive malnutrition ensues.
Weight loss and low BMI, especially when associated with low
CD4 cell counts, are strong and independent predictors of sur-
vival in HIV infection [20]. Similarly, lower levels of hemo-
globin, albumin, and serum cholesterol have been identified as
predictors of faster disease progression and decreased survival
[21, 22]. The long-term prognosis in patients with severe weight
loss is guarded, especially when patients are waiting or not
willing to start ART. Studies have also documented the dele-
terious effect of tuberculosis and other opportunistic infections
on nutritional status (infection and malnutrition often form a
vicious cycle, along with poverty and food insecurity) [5, 23,
24]. Preventing weight loss, therefore, could potentially have
multiple benefits in terms of reducing mortality and morbidity,
contributing to increased productivity and economic stability
and perhaps improving responses to ART. Although there have
been many calls for integration of HIV and nutrition programs,
data are lacking on how such programs can be implemented
in resource-constrained settings, what the composition of the
supplement should be, and which subgroups should be target-
ed [25].
Our study has made important contributions to the limited
knowledge base in this field. We have demonstrated the ac-
ceptability and feasibility of providing macronutrient supple-
ments using a clinic-based approach in this largely food-in-
secure population. Sharing of food supplements among family
members was not encouraged, but additional supplies were
provided if requested so that the patients in this study could
take the recommended 100 g per day. We showed significant
improvements in various nutritional parameters and docu-
mented a slower decrease in CD4 cell counts among patients
who were provided supplements. The absolute gains in weight,
BMI, CD4 cell count, fat-free mass, and body cell mass were
higher among patients with severe immunodeficiency, indicat-
ing that demonstrable improvements are most likely to be seen
among the most immunosuppressed, who are also the most
malnourished. However, changes in body composition as mea-
sured by the bioimpedance analyzer are not reliable, especially
in patient populations with shifts in hydration [26]. The ques-
tion of the most appropriate stage of HIV infection at which
supplementation is likely to have a maximum benefit remains
to be answered. Furthermore, our study included an HIV-in-
fected comparison group as a control, was conducted in real-
life situations, was clinic based, and did not have strict inclusion
and exclusion criteria. Patients were free to initiate ART or
withdraw from the study at any time, and we had patients at
all stages of HIV disease. It also brought out practical problems,
such as difficulty in proper storage of flour (due to humidity),
early satiety during consumption, difficulty in preparation, and
boredom with the same food item. Nevertheless, most patients
opted to continue taking the supplements even after the study
period ended.
Policy makers in resource-poor regions need information on
both the efficacy and feasibility of providing nutritional sup-
plements (of various types) in different settings [18, 27]. The
state of Tamil Nadu in India implemented a macronutrient
supplementation program for all HIV-infected patients initi-
ating ART at government ART centers. Three of these sites had
additional resources from the Children’s Investment Fund
Foundation in the United States and provided a supplement
similar to that used in our study to all patients attending the
center regardless of ART status. The ART-naive patients showed
a weight gain of 2.7 kg ( ) for 1 year, after controllingP ! .01
for supplementation adherence, number of nutritional coun-
seling sessions, and sex. Furthermore, a weight gain of 300 g
for every 10% increase in adherence to the macronutrient sup-
plement regimen was observed, after adjusting for ART, mi-
cronutrient supplement regimen adherence, and counseling
[28]. The program was appreciated by patients, provided an
incentive for regular attendance, and is being replicated in oth-
er states in India.
In summary, an energy-dense oral macronutrient supple-
ment did not have additional benefits on nutritional parame-
ters or immune function among ART-naive HIV-infected in-
dividuals in South India, compared with high-quality standard
of care. The effect of supplementation on specific subsets of
patients and on preserving immune function needs further re-
search.
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